Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer.

about

Loss of RASSF1A expression in colorectal cancer and its association with K-ras status.A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors.EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients.

P2860

Q36995731-95CB3B5B-EC2C-4635-8FEE-2A798C801AD8 Q38399733-2F622386-89D8-4867-8F62-57E2EDFE4790 Q49861198-A2E51413-1972-4400-8D33-CCEC32E49205

P2860

Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer.

Item

http://www.wikidata.org/entity/Q36321184

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Antiepidermal growth factor re ...... ications in colorectal cancer.

@ast

Antiepidermal growth factor re ...... ications in colorectal cancer.

@en

type

Item

label

Antiepidermal growth factor re ...... ications in colorectal cancer.

@ast

Antiepidermal growth factor re ...... ications in colorectal cancer.

@en

prefLabel

Antiepidermal growth factor re ...... ications in colorectal cancer.

@ast

Antiepidermal growth factor re ...... ications in colorectal cancer.

@en

P1476

Antiepidermal growth factor re ...... ications in colorectal cancer.

@en

P2093

Adam Kittai

http://www.w3.org/2001/XMLSchema#string

Efat Azizi

http://www.w3.org/2001/XMLSchema#string

Peter Kozuch

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

P304

198197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/198197

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232612167

http://www.w3.org/2001/XMLSchema#string

P698

23091721

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3472558

http://www.w3.org/2001/XMLSchema#string

Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer.

about

P2860

P2860

Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932